Kamada Reports Record 2025 Results and Affirms Double-Digit Growth Outlook for 2026

Key Facts

1Kamada reported record top-line and bottom-line financial results for the full year 2025.

2The company affirmed its 2026 guidance, representing continued double-digit organic profitable growth.

3Kamada operates in the biopharmaceutical field, specializing in plasma-derived products for rare and serious conditions.

Kamada Ltd. (NASDAQ: KMDA) announced record-breaking financial performance for the fiscal year 2025, achieving all-time highs in both revenue and profitability. The specialty biopharmaceutical company attributed its success to the strong performance of its portfolio of plasma-derived products targeting rare and serious conditions. Following these results, management reaffirmed its financial guidance for 2026, projecting continued organic growth exceeding 10%. This positive outlook reflects the company's leadership position in the niche plasma-derived therapeutics market. Investors are reacting positively to the combination of current record earnings and the sustained growth trajectory expected for the coming year. The company remains focused on expanding its market share and advancing its pipeline of specialized treatments.